Targeted treatment of prostate cancer

Journal of Cellular Biochemistry

Volumn 102, Issue 3, 2007, Pages 571-579

  Wang, Xinning ^a   Yin, Lihong ^a   Rao, Pravin ^a   Stein, Robert ^a   Harsch, Kelley M ^a   Lee, Zhenghong ^b   Heston, Warren D W ^a,c  

^a LERNER RESEARCH INSTITUTE   (United States)

^b Case Western Reserve University   (United States)

^c NONE   (United States)

Author keywords

Prostate cancer; Prostate specific antigen (PSA); Prostate specific membrane antigen (PSMA)

Indexed keywords

8 O (12 AMINODODECANOYL) 8 O DEBUTANOYLTHAPSIGARGIN; ANDROGEN RECEPTOR; APTAMER; CAPROMAB PENDETIDE IN 111; DOLOSTATIN; DOXORUBICIN; FOLIC ACID DERIVATIVE; GELONIN; LEXIDRONAM SAMARIUM SM 153; METHOTREXATE; MONOCLONAL ANTIBODY J591 LUTETIUM 177; MONOCLONAL ANTIBODY J591 YTTRIUM 90; N ACETYLASPARTYLGLUTAMIC ACID; PROAEROLYSIN; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; THAPSIGARGIN; THIOUREA DERIVATIVE; TOXIN; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; BONE MARROW TOXICITY; CLINICAL TRIAL; DIAGNOSTIC VALUE; DRUG EFFECT; DRUG EFFICACY; DRUG TARGETING; HUMAN; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; UPREGULATION;

ANDROGENS; ANIMALS; ANTIGENS, SURFACE; CELL MEMBRANE; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; IMMUNE SYSTEM; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; LIGANDS; MALE; MODELS, BIOLOGICAL; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; RECEPTORS, ANTIGEN; T-LYMPHOCYTES;

EID: 35048896107     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.21491     Document Type: Review

References (46)

1. Bacich DJ, Wozniak KM, Lu XC, O'Keefe DS, Callizot N, Heston WD, Slusher BS. 2005. Mice lacking glutamate carboxypeptidase II [psma] are protected from peripheral neuropathy and ischemic brain injury. J Neurochem 95: 314-323.
2. Bander NH, Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ. 2005. Phase I trials of 177-Lutecium labeled J591, a monoclonal antibody to prostate-specific membrane antigen in patients with androgen-independent prostate cancer. J Clin Oncol 23: 4591-4601.
3. Barwe SP, Maul RS, Christiansen JJ, Anilkumar G, Cooper CR, Kohn DB, Rajasekaran AK. 2007. Preferential association of prostate cancer cells expressing prostate specific membrane antigen to bone marrow matrix. Int J Oncol 30:899-904.
4. Bettoun DJ, Scafonas A, Rutledge SJ, Hodor P, Chen O, Gambone C, Vogel R, McElwee-Witmar S, Bai C, Freedman L, Schmidt A. 2005. Interaction between the androgen receptor and RNaseL mediates a cross-talk between the interferon and androgen signaling systems. J Biol Chem 280:38898-38901.
5. Burdelya LG, Komarova EA, Hill JE, Browder T, Taraova ND, Mavrakis L, DiCorleto PE, Folkman J, Gudkov AV. 2006. Inhibition of p53 response in tumor stroma improves efficacy of anticancer treatment by increasing antiangiogenic effects of chemotherapy and radiotherapy in mice. Cancer Res 66:9356-9361.
6. Chu TC, Marks JW, III, Lavery LA, Faulkner S, Rosenblum MG, Ellington AD, Levy M. 2006. Aptamer: Toxin conjugates that specifically target prostate tumor cells. Cancer Res 66:5989-5992.
7. Collins AT, Maitland NJ. 2006. Prostate cancer stem cells. Eur J Cancer 42:1213-1218.
8. Conway RE, Petrovic N, Li Z, Heston WDW, Wu D, Shapiro LH. 2006. Prostate-specific membrane antigen regulates angiogenesis by modulating integrin signal transduction. Mol Cell Biol 26:5310-5324.
9. Culig Z. 2004. Androgen receptor cross-talk with cell signaling pathways. Growth Factors 22:179-184.
10. Davis MI, Bennett MJ, Thomas LM, Bjorkman PJ. 2005. Crystal structure of prostate-specific membrane antigen, a tumor marker and peptidase. Proc Natl Acad Sci U S A 102:5981-5986.
11. Dehm SM, Tindall DJ. 2006. Molecular regulation of androgen action in prostate cancer. J Cell Biochem 99:333-344.
12. Foss Ca, Mease RC, Fan H, Wang Y, Ravert HT, Dannals RF, Olszewski RT, Heston WD, Kozikowski AP, Pomper MG. 2005. Radiolabeled small molecule ligands for prostate-specific membrane antigen: In vivo imaging in experimental models of prostate cancer. Clin Cancer Res 11:4022-4028.
13. Gade TPE, Hassen W, Santos E, Gunset G, Saudemont A, Gong MC, Brentjens ER, Zhong X-S, Stephan M, Stefanski J, Lyddane C, Osborne JR, Buchanan IM, Hall SJ, Heston WD, Riviere I, Larson SM, Koutcher JA, Sadelain M. 2005. Targeted elimination of prostate cancer by genetically directed human T-lymphocytes. Cancer Res 65:9080-9088.
14. Ghosh A, Heston WSDW. 2004. Tumor target prostate-specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem 91:528-539.
15. Hendriksen PJ, Dits NF, Kokame K, Veldhoven A, van Weerden WM, Bangma CH, Trapman J, Jenster G. 2006. Evolution of the androgen receptor pathway during progression of prostate cancer. Cancer Res 66:5012-5020.
16. Heston WW, Tong WP, Pinro JT. 1997. Prostate-specific membrane antigen, a unique folate hydrolase: Potential target for prodrug therapy. Mol Urol 1:215-219.
17. Israeli RS, Powell CT, Corr JG, Fair WR, Heston WDW. 1994. Expression of prostate-specific membrane antigen. Cancer Res 54:1807-1811.
18. Jayprakash A, Wang X, Heston WD, Kozikowski AP. 2006. Design and synthesis of a PSMA inhibitor-doxorubicin conjugate for targeted prostate cancer therapy. Chem Med Chem 13:299-302.
19. Liu H, Rajasekaran AK, Moy P, Xia Y, Kim S, Navarro V, Rahmati R, Bander NH. 1998. Constitutive and antibody induced internalization of prostate-specific membrane antigen. Cancer Res 58:4055-4060.
20. Lupoid SE, Rodriquez R. 2004. Disulfide-constrained peptides that bind to the extracellular portion of the prostate-specific membrane antigen. Mol Cancer Ther 3:597-603.
21. Lupoid SE, Hicke BJ, Lin Y, Coffey DS. 2002. Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen. Cancer Res 62:4029-4033.
22. Ma D, Hopf CE, Malewicz AD, Donovan GP, Senter PD, Goeckler WF, Maddon PJ, Olson WC. 2006. Potent antitumor activity of an auristatin-conjugated, fully human monoclonal antibody to prostate-specific membrane antigen. Clin Cancer Res 12:2591-2596.
23. Meraney AM, Heston WDW. 2007. Recombinant antibody candidates for the treatment of prostate cancer. In: Chung LWK, Isaacs WB, Simons JW, editors. Contemporary cancer research: Prostate cancer: Biology, genetics, and the new therapeutics. 2nd edition. Totawa NJ: Humana Press, Inc. pp 395-408.
24. Mesters JR, Barinka C, Li W, Tsukamoto T, Majer P, Slusher BS, Konvalinka J, Hilgenfeld R. 2006. Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer. EMBO J 25: 1375-1384.
25. Mhaka A, Singh P, Rosen M, Dionne CA, Christensen SB, Isaacs JT, Denmeade SR. 2006. Prostate-Specific membrane Antigen (PSMA) targeted prodrug "smartbombs" as therapy for prostate cancer. Proc Amer Assoc Cancer Res 47: Abstact #3081.
26. Milas L, Milas MM, Mason KA. 1999. Combination of taxanes with radiation: Preclinical studies. Semin Radiat Oncol 9:12-26.
27. Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ, Bander NH. 2004. Phase I trial of Yittium-90 labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer. J Clin Oncol 22:2522-2531.
28. Milowsky MI, Nanus DM, Kostakoglu L, Sheehan CE, Vallbhajosula S, Goldsmith SJ, Ross JS, Bander NH. 2007. Vascular targeted therapy with anti-prostate specific membrane antigen monoclonal antibody J591 in advanced solid tumors. J Clin Oncol 10:540-546.
29. Mostaghel EA, Page ST, Lin DW, Fazli L, Coleman IM, True LD, Knudsen B, Hess DL, Nelson CC, Matsumoto AM, Bremner WJ, Gleave ME, Nelson PS. 2007. Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: Therapeutic implications for castration resistant prostate cancer. Cancer Res 67:5033-5041.
30. Nikitin AY, Matoso A, Roy-Burman P. 2007. Prostate stem cells and cancer. Histol Histopathol 22:1043-1049.
31. Perner S, Hofer MD, Kim R, Shah RB, Li H, Moller P, Hautmann RE, Gschwend JE, Kuefer R, Rubin MA. 2007. Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. Hum Pathol 38:696-701.
32. Rajasekaran SA, Anilkumar G, Oshima E, Bowie JU, Liu H, Heston WDW, Bander NH, Rajasekaran AK. 2003a. A novel cytoplasminc tail MXXXL motif mediates the internalization of prostate specific membrane antigen. Mol Biol Cell 14:4835-4845.
33. Rajasekaran AG, Rajasekaran SA, Wang S, Hankinson O, Bander NH, Rajasekaran AK. 2003b. Prostate-specific membrane antigen association with filamin A modulates its internalization and NAALADASE activity. Cancer Res 63:2645-2648.
34. Ross JS, Sheehan CE, Fisher HA, Kaufman RP, Kaur P, Gray K, Webb I, Gray GS, Mosher R, Kallakury BV. 2003. Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. Clin Cancer Res 15:6357-6362.
35. Sacha P, Zamecnik J, Barinka C, Hlouchova K, Vicha A, Mlcochova P, Hilgert I, Eckschlager T, Konvalinka J. 2007. Expression of glutamate carboxypeptidase II in human brain. Neuroscience 144:1361-1372.
36. Sartor O, Reid RH, Bushneil DL, Quick DP, Ell PJ. 2007. Safety and efficacy of repeat administration of samarium Sm-153 lexidronam to patients with metastatic bone pain. Cancer 109:637-643.
37. Scher HI, Leibel SA, Fuks Z, Cordon-Cardo C, Scardino PT. 2005. Cancer of the Prostate. In: DeVita VT Jr, Hellman S, Rosenberg SA, editors. Cancer. Principles and practice of oncology. 7th edition. Philadelphia PA: Lippincott Williams and Wilkins. pp 1192-1259.
38. Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, Mandelka D, Leary RJ, Ptak J, Stilman N, Szabo S, Bickhaults P, Farrell C, Meeh P, Markowitz SD, Willis J, Dawson D, Wilson JKV, Gazdar AF, Hartgan J, Wu L, Liu C, Parmigiana G, Park BH, Bachman KE, Papadopoulos N, Volgelstein B, Kanzler KW, Velculescu VE. 2006. The consensus coding sequences of human breast and colorectal cancers. Science 314:268-274.
39. Tasch J, Gong M, Sadelain M, Heston WDW. 2001. A unique folate hydrolase, prostate-specific membrane antigen (PSMA): A target for immunotherapy? Crit Rev Immunol 21:249-261.
40. Tindall D, Horne FM, Hruszkewycz A, Mohla S, Shuman M, Wang Z, Kantoff P. 2004. Symposium on androgen action in prostate cancer. Cancer Res 64:7178-7180.
41. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun X-W, Varambally S, Cao X, Tchinda J, Kuefer R, Lee C, Montie JE, Shah RB, Pienta KJ, Rubin MA, Chinnaiyan AM. 2005. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310:644-648.
42. Vallabhajosula S, Goldsmith SJ, Hamacher KA, Kostakoglu L, Konishi S, Milowski MI, Nanus DM, Bander NH. 2005a, Prediction of myelotoxicity based on bone marrow radiation-absorbed dose: Radioimmunotherapy studies using 90-Y and 177-Lu labeled J591 antibodies specific for prostate specific membrane antigen. J Nuc Med 46:850-858.
43. Vallabhajosula S, Kuji I, Hamacher KA, Konishi S, Kostakoglu L, Kothari PA, Milowski MI, Nanus DM, Bander NH, Goldsmith SJ. 2005b. Pharmacokinetics and biodistribution of 111-In and 177-Lu labeled J 591 antibody specific for prostate-specific membrane antigen: Prediction of 90Y-j591 radiation dosimetry based on 111-In of 177-Lu. J Nuc Med 46:634-641.
44. Wang S, Garcia AJ, Wu M, Lawson DA, Witte ON, Wu H. 2006. Pten deletion leads to the expansion of a prostatic stem/progenitor cell subpopulation and tumor initiation. Proc Natl Acad Sci U S A 103:1480-1485.
45. Williams SA, Merchant RF, Garrett-Mayer E, Isaacs JT, Buckley JT, Denmeade SR. 2007. A prostate-specific antigen-activated channel-forming toxin as therapy for prostatic disease. J Natl Cancer Inst 99:376-385.
46. Wu JD, Haugk K, Woodke L, Nelson P, Coleman I, Plymate SR. 2006. Interaction of IGF signaling and the androgen receptor in prostate cancer progression. J Cell Biochem 99:392-401.